---
title: "Sex differences in genetic links between modifiable risk factors and Alzheimer’s disease"
id: "medrxiv-15-sex-differences-in-genetic-liability-to-modifiable-alzheimer-s-disease-risk"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-15-sex-differences-in-genetic-liability-to-modifiable-alzheimer-s-disease-risk"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.01.26364536v1?rss=1"
published_at: "2026-10-06T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Sex differences in genetic links between modifiable risk factors and Alzheimer’s disease
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-15-sex-differences-in-genetic-liability-to-modifiable-alzheimer-s-disease-risk
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.01.26364536v1?rss=1)
- **Published At:** 2026-10-06T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The study evaluated whether inherited genetic liability to **modifiable dementia risk factors** associates differently with Alzheimer's disease (AD) in females versus males. - Investigators used three complementary genetic approaches: polygenic risk scores (PRS), genome-wide genetic correlation, and two-sample Mendelian randomization (MR). - PRS associations with clinical AD were tested in the Alzheimer's Disease Genetics Consortium (ADGC; n=27,751) and with plasma AD biomarkers in the Health and Aging Brain Study–Health Disparities (HABS‑HD; n=2,307–2,737 depending on biomarker). - Primary PRS results: PRSs for **educational attainment** and **physical activity** were associated with AD diagnosis in both sexes. Some PRS sex differences were nominally observed for educational attainment, total cholesterol, and LDL cholesterol but none survived false discovery rate (FDR) correction. - Genome-wide genetic correlation analyses identified FDR-significant sex differences for **social isolation**, **physical activity**, **LDL cholesterol**, and **pulse pressure**, indicating sex-differing shared genetic architecture for these traits and AD. - Two-sample MR detected FDR-significant within-sex associations: higher **HDL cholesterol** associated with lower AD risk in females; higher **total cholesterol** and **type 2 diabetes** associated respectively with lower and higher AD risk in males. Sensitivity analyses gave inconsistent support, and no MR sex-difference estimate remained significant after FDR correction. - In HABS‑HD plasma biomarker analyses, among males the **type 2 diabetes** PRS associated with higher neurofilament light (NfL), **BMI** PRS associated with higher pTau181, and a composite PRS associated with higher NfL after FDR correction. - Overall conclusion: evidence for sex-specific relationships between genetic liability to modifiable risk factors and AD was limited and method-dependent; genome-wide overlap did not consistently translate into sex-specific PRS associations or causal effects by MR. - Data sources, supplementary tables, and code availability were reported; the manuscript is a preprint and not peer reviewed, and authors report no competing interests.
## Clinical Analysis & Structured Key Points
Sex differences in genetic liability to modifiable Alzheimer's disease risk factors | medRxiv Skip to main content Sex differences in genetic liability to modifiable Alzheimer's disease risk factors View ORCID Profile Rakshya U Sharma , View ORCID Profile Paulina Tolosa-Tort , View ORCID Profile Meri Okorie , View ORCID Profile Aadrita Chatterjee , View ORCID Profile Caroline Jonson , View ORCID Profile Kristine Yaffe , View ORCID Profile Michael E Belloy , View ORCID Profile Shea J Andrews , ADGC , HABS-HD Study team doi: https://doi.org/10.64898/2026.10.01.26364536 Rakshya U Sharma 1 University of California, San Francisco; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Rakshya U Sharma Paulina Tolosa-Tort 1 University of California, San Francisco; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Paulina Tolosa-Tort Meri Okorie 1 University of California, San Francisco; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Meri Okorie Aadrita Chatterjee 1 University of California, San Francisco; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Aadrita Chatterjee Caroline Jonson 2 DataTecnica LLC; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Caroline Jonson Kristine Yaffe 3 University of California San Francisco; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Kristine Yaffe Michael E Belloy 4 Washington University in St. Louis Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Michael E Belloy Shea J Andrews 3 University of California San Francisco; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Shea J Andrews For correspondence: shea.andrews{at}ucsf.edu Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract NTRODUCTION: Alzheimer's disease (AD) shows sex differences in risk, clinical progression, and biomarker profiles, but whether inherited genetic liability to modifiable risk factors contributes differently to AD susceptibility in females and males remains unclear. We evaluated whether genetic relationships between several modifiable dementia risk factors and AD differ between females and males. METHODS: We integrated polygenic risk scores (PRSs) for modifiable risk factors, genome-wide genetic correlation, and two-sample Mendelian randomization (MR) analyses. PRS associations with AD diagnosis were evaluated in the Alzheimer's Disease Genetics Consortium (n=27,751) and with AD plasma biomarkers in the Health and Aging Brain Study-Health Disparities (n=2,307-2,737, depending on the biomarker). Primary analyses evaluated female- and male-specific associations and compared sex-specific estimates. RESULTS: Educational attainment and physical activity PRSs were associated with AD in both sexes. PRS sex differences were nominal for educational attainment, total cholesterol, and LDL cholesterol, but none remained significant after FDR correction. Genetic correlation showed FDR-significant sex differences for social isolation, physical activity, LDL cholesterol, and pulse pressure. MR identified FDR-significant associations within sex strata; higher HDL cholesterol was associated with lower AD risk in females, whereas higher total cholesterol and type 2 diabetes were associated with lower and higher AD risk, respectively, in males. Sensitivity analyses provided inconsistent support, and no sex difference in MR estimates remained significant after FDR correction. In HABS-HD, type 2 diabetes PRS was associated with higher NfL, BMI PRS with higher pTau181, and the composite PRS with higher NfL among males after FDR correction. DISCUSSION: Evidence that modifiable dementia risk factors relate differently to AD by sex was limited and depended on the genetic measure examined. Sex differences in genome-wide genetic overlap were not consistently reflected in PRS or MR, indicating that shared genetic architecture does not necessarily translate into sex-specific inherited liability or causal effects Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: ADGC: Written informed consent was obtained from study participants or, for those with substantial cognitive impairment, from a caregiver, legal guardian, or other proxy, and the study protocols for all populations were reviewed and approved by the appropriate institutional review boards (IRBs). HABS-HD: All HABS-HD participants (and/or their legal guardians) signed written informed consent to participate in the study. De-identified individual-level data and aggregated/summary data. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability Data for ADGC and HABS-HD are available from https://www.adgenetics.org/ and https://healthandagingbrainstudy.org/, respectively. Information about the GWAS Summary statistics used for each trait is provided in Supplementary Table S1. https://www.adgenetics.org/ https://healthandagingbrainstudy.org/ Funder Information Declared National Institutes of Health, https://ror.org/01cwqze88 , R00AG070109A Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted October 06, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Sex differences in genetic liability to modifiable Alzheimer's disease risk factors Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Sex differences in genetic liability to modifiable Alzheimer's disease risk factors Rakshya U Sharma , Paulina Tolosa-Tort , Meri Okorie , Aadrita Chatterjee , Caroline Jonson , Kristine Yaffe , Michael E Belloy , Shea J Andrews , ADGC , HABS-HD Study team medRxiv 2026.10.01.26364536; doi: https://doi.org/10.64898/2026.10.01.26364536 Share This Article: Copy Citation Tools Sex differences in genetic liability to modifiable Alzheimer's disease risk factors Rakshya U Sharma , Paulina Tolosa-Tort , Meri Okorie , Aadrita Chatterjee , Caroline Jonson , Kristine Yaffe , Michael E Belloy , Shea J Andrews , ADGC , HABS-HD Study team medRxiv 2026.10.01.26364536; doi: https://doi.org/10.64898/2026.10.01.26364536 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Area Genetic and Genomic Medicine Subject Areas All Articles Addiction Medicine (626) Allergy and Immunology (914) Anesthesia (340) Cardiovascular Medicine (4885) Dentistry and Oral Medicine (486) Dermatology (421) Emergency Medicine (659) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1643) Epidemiology (16064) Forensic Medicine (34) Gastroenterology (1218) Genetic and Genomic Medicine (7128) Geriatric Medicine (736) Health Economics (1073) Health Informatics (5124) Health Policy (1447) Health Systems and Quality Improvement (1793) Hematology (590) HIV/AIDS (1355) Infectious Diseases (except HIV/AIDS) (16360) Intensive Care and Critical Care Medicine (1184) Medical Education (678) Medical Ethics (156) Nephrology (729) Neurology (7386) Nursing (370) Nutrition (1102) Obstetrics and Gynecology (1263) Occupational and Environmental Health (1010) Oncology (3658) Ophthalmology (1066) Orthopedics (399) Otolaryngology (459) Pain Medicine (483) Palliative Medicine (142) Pathology (711) Pediatrics (1822) Pharmacology and Therapeutics (741) Primary Care Research (776) Psychiatry and Clinical Psychology (5986) Public and Global Health (9835) Radiology and Imaging (2464) Rehabilitation Medicine and Physical Therapy (1479) Respiratory Medicine (1257) Rheumatology (651) Sexual and Reproductive Health (786) Sports Medicine (588) Surgery (786) Toxicology (107) Transplantation (310) Urology (298)
## Related Clinical Research

- [AD-Smart trial to repurpose diabetes and ADHD drugs for Alzheimer’s patients](https://medichelpline.com/clinical-feed/bmj-0-ad-smart-alzheimer-x2019-s-trial-will-test-diabetes-and-adhd-drugs-on-patients.md)
- [Ultra-processed foods linked to MRI signs of vascular brain injury in middle-aged adults](https://medichelpline.com/clinical-feed/medical-news-today-0-ultra-processed-foods-may-be-harming-brain-health-in-otherwise-healthy-adults.md)
- [Global dementia incidence projected to reach 24.7 million new cases annually by 2050](https://medichelpline.com/clinical-feed/medical-news-today-0-dementia-cases-to-double-by-2050-why-women-some-countries-may-be-at-higher-risk.md)
- [Education and Alzheimer’s Genetic Risk Do Not Explain GLP-1 RA Associations With Dementia in Type](https://medichelpline.com/clinical-feed/medrxiv-23-education-and-alzheimer-disease-genetic-risk-in-associations-of-glp-1-receptor.md)
- [GLP‑1 Receptor Agonists and SGLT2 Inhibitors Linked to Lower Alzheimer Risk in Type 2 Diabetes](https://medichelpline.com/clinical-feed/medrxiv-20-glp-1-receptor-agonists-vs-sglt2-inhibitors-for-alzheimer-disease-risk-in-type.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.